FDA Rejects Noven Fentanyl Patch ANDA Due To Safety Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency will cease reviewing Noven/Endo’s generic version of J&J’s Duragesic chronic pain therapy due to a higher drug content in the pending ANDA.
You may also be interested in...
Lavipharm Transdermal Fentanyl Patch Generic Approved By FDA
Greek drug maker said it plans to launch the generic of J&J/Alza's Duragesic patch with a U.S. partner, which it has yet to announce.
Lavipharm Transdermal Fentanyl Patch Generic Approved By FDA
Greek drug maker said it plans to launch the generic of J&J/Alza's Duragesic patch with a U.S. partner, which it has yet to announce.
Duragesic Public Health Advisory Follows Palladone Withdrawal
FDA is investigating reports of deaths associated with overdoses of the fentanyl patch (J&J’s Duragesic and generics). As with Purdue’s opioid Palladone, alcohol consumption is cited as a possible factor in increased fentanyl release or effect.